                         SEQUENCE LISTING

<110>  Mayo Foundation for Medical Education and Research
 
<120>  MONOVALENT ANTI-CD3 ADJUVANTS

<130>  07039-1523WO1

<150>  US 62/280,477
<151>  2016-01-19

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  104
<212>  PRT
<213>  Homo sapiens

<400>  1

Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys Val 
1               5                   10                  15      


Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro Gly 
            20                  25                  30          


Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp Glu 
        35                  40                  45              


Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys Glu 
    50                  55                  60                  


Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly 
65                  70                  75                  80  


Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg Val 
                85                  90                  95      


Cys Glu Asn Cys Met Glu Met Asp 
            100                 


<210>  2
<211>  104
<212>  PRT
<213>  Homo sapiens

<400>  2

Ala Ile Ile Leu Leu Gln Gly Thr Leu Ala Gln Ser Ile Lys Gly Asn 
1               5                   10                  15      


His Leu Val Lys Val Tyr Asp Tyr Gln Glu Asp Gly Ser Val Leu Leu 
            20                  25                  30          


Thr Cys Asp Ala Glu Ala Lys Asn Ile Thr Trp Phe Lys Asp Gly Lys 
        35                  40                  45              


Met Ile Gly Phe Leu Thr Glu Asp Lys Lys Lys Trp Asn Leu Gly Ser 
    50                  55                  60                  


Asn Ala Lys Asp Pro Arg Gly Met Tyr Gln Cys Lys Gly Ser Gln Asn 
65                  70                  75                  80  


Lys Ser Lys Pro Leu Gln Val Tyr Tyr Arg Met Cys Gln Asn Cys Ile 
                85                  90                  95      


Glu Leu Asn Ala Ala Thr Ile Ser 
            100                 


<210>  3
<211>  94
<212>  PRT
<213>  Homo sapiens

<400>  3

Leu Ala Thr Leu Leu Ser Gln Val Ser Pro Phe Lys Ile Pro Ile Glu 
1               5                   10                  15      


Glu Leu Glu Asp Arg Val Phe Val Asn Cys Asn Thr Ser Ile Thr Trp 
            20                  25                  30          


Val Glu Gly Thr Val Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp 
        35                  40                  45              


Leu Gly Lys Arg Ile Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly 
    50                  55                  60                  


Thr Asp Ile Tyr Lys Asp Lys Glu Ser Thr Val Gln Val His Tyr Arg 
65                  70                  75                  80  


Met Cys Gln Ser Cys Val Glu Leu Asp Pro Ala Thr Val Ala 
                85                  90                  


<210>  4
<211>  94
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic human FN3 sequence

<400>  4

Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 
1               5                   10                  15      


Ser Leu Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr 
            20                  25                  30          


Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 
        35                  40                  45              


Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro 
    50                  55                  60                  


Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg Gly Asp 
65                  70                  75                  80  


Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg Thr 
                85                  90                  


